Earnings Feed
Start Free
Entrada Therapeutics, Inc.·4

Mar 3, 6:18 PM ET

Sethuraman Natarajan 4

4 · Entrada Therapeutics, Inc. · Filed Mar 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Entrada Therapeutics (TRDA) President Sethuraman Natarajan Receives Award

What Happened

  • Sethuraman Natarajan, President of Research & Development at Entrada Therapeutics, was granted equity awards and had shares sold by the company to cover tax withholdings. On 2026-03-01 the company granted 55,800 shares and an additional 83,200 RSUs (total 139,000 RSUs) at $0.00 (derivative award). To satisfy required tax withholding, the company automatically sold 3,898 shares on 2026-03-02 for a weighted average price of $11.66 (proceeds $45,442) and 7,577 shares on 2026-03-03 for a weighted average price of $11.76 (proceeds $89,078). Total shares sold: 11,475 for aggregate proceeds of ~$134,520.
  • These sales were automatic sell-to-cover transactions to satisfy statutory tax obligations (not discretionary sales by the insider).

Key Details

  • Transaction dates: RSU grants on 2026-03-01; sell-to-cover on 2026-03-02 and 2026-03-03.
  • Sale prices/notes: 3,898 shares at weighted avg $11.66 (range $11.17–$11.91); 7,577 shares at weighted avg $11.76 (range $11.22–$12.095). (Per filing, full per-price breakdown is available on request.)
  • Shares acquired: 139,000 RSUs (two entries: 55,800 and 83,200). Shares disposed: 11,475 (sell-to-cover).
  • Shares owned after transaction: Not disclosed in this filing.
  • Notable footnotes: F1—RSUs vest 25% each year from March 1, 2027–2030; F2—sales were mandatory sell-to-cover; F3/F4—weighted-average sale prices with reported ranges.
  • Filing timeliness: Form 4 filed 2026-03-03 covering transactions dated 2026-03-01 through 03-03; filing appears timely per standard Form 4 rules.

Context

  • These were RSU awards (derivative grants) with multi-year vesting; RSUs convert to common shares only as they vest. The share sales were automatic sell-to-cover to pay withholding taxes and do not necessarily indicate the insider’s trading intent.

Insider Transaction Report

Form 4
Period: 2026-03-01
Entrada Therapeutics, Inc.TRDA
Sethuraman Natarajan
President, Research & Develop.
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-01+55,800→ 253,699 total
  • Tax Payment

    Common Stock

    [F2][F3]
    2026-03-02$11.66/sh−3,898$45,442→ 249,801 total
  • Tax Payment

    Common Stock

    [F2][F4]
    2026-03-03$11.76/sh−7,577$89,078→ 242,224 total
  • Award

    Stock Option (Right to Buy)

    [F5]
    2026-03-01+83,200→ 83,200 total
    Exercise: $11.93Exp: 2036-03-01→ Common Stock (83,200 underlying)
Footnotes (5)
  • [F1]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
  • [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.
Signature
/s/ Jared Cohen, as Attorney-in-Fact|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772579932.xmlPrimary

    FORM 4